A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 12, 2019

Primary Completion Date

September 28, 2022

Study Completion Date

June 28, 2023

Conditions

Multiple MyelomaRelapsed and Refractory Multiple Myeloma

Interventions

DRUG

HG146

HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.

Trial Locations (1)

HitGen Inc, Chengdu